Abstract: An appliance hub for use in an upper portion of an enclosure can include a substrate configured to be positioned in an upper portion of an enclosure. The appliance hub can include a climate control apparatus mounted on the substrate and the climate control apparatus can be configured to regulate a temperature within the enclosure. The appliance hub can include one or more lighting elements configured to provide light within the enclosure, a plurality of fluid lines connected to the substrate and configured to provide fluid service and return to the climate control apparatus, and/or a plurality of electrical connections connected to the substrate and configured to provide electrical power and/or data to at least one of the climate control apparatus and the one or more lighting elements.

Abstract: A modular expansion joint system with equidistance control. The modular expansion joint system includes transverse vehicle load bearing members which are positioned in a gap defined between adjacent spaced-apart structural members, support members positioned below the transverse vehicle load bearing members and extending across the expansion joint gap between the adjacent structural members, means positioned within the structural members for controlling movement of the support members, and means for controlling the spacing between the transverse vehicle load bearing members. The means for controlling the distance between the transverse vehicle load bearing members comprises a non-elastomeric compressive member, such as at least one coil spring which, which according to certain illustrative embodiments, maintains a substantially equal distance between transverse vehicle load bearing members.

Abstract: A modular expansion joint system with equidistance control. The modular expansion joint system includes transverse vehicle load bearing members which are positioned in a gap defined between adjacent spaced-apart structural members, support members positioned below the transverse vehicle load bearing members and extending across the expansion joint gap between the adjacent structural members, means positioned within the structural members for controlling movement of the support members, and means for controlling the spacing between the transverse vehicle load bearing members. The means for controlling the distance between the transverse vehicle load bearing members comprises a non-elastomeric compressive member, such as at least one coil spring which, which according to certain illustrative embodiments, maintains a substantially equal distance between transverse vehicle load bearing members.

Abstract: An expansion joint system for bridging a gap between spaced apart structural members and capable of self-cleaning. The expansion joint system includes first and second base members, at least one upwardly sloped base plate engaged with one of the first and second base members, and at least one substantially horizontal movable plate engaged with at least one of the first and second base members. Also disclosed is an expansion joint including a first structural member and a second structural member, first and second base members, at least one upwardly sloped base plate engaged with one of the first and second base members, and at least one substantially horizontal movable plate engaged with at least one of the first and second base members.

Abstract: A component for a gas turbine engine, including: at least one internal cavity extending through the component, the internal cavity having at least one inlet opening and at least one outlet opening each being in fluid communication with the at least one internal cavity; a plurality of cooling features extending from a surface of the at least one internal cavity, the plurality of cooling features are formed in accordance with at least one of the following groups: i) a plurality of airfoil shaped features that extend upwardly from the surface of the at least one internal cavity and a plurality of wedge shaped features each having a triangular base that has an upstream portion and a downstream portion, the upstream portion extending further from the surface than the downstream portion; ii) a plurality features having a curved or “J” shaped base that extends upwardly from the surface, a plurality features having a double curved or symmetrically “J” shaped base that extends upwardly from the surface, and a pluralit

Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

Abstract: A system and method for visually warning a person of a dangerous condition related to the proximity of the person to a machine is provided. The system includes a transmitter system located on the machine, a locator for being carried by the person, an algorithm performed at the transmitter for determining coordinates of the locator relative to the transmitter system, data input into the controller defining one or more safety zones around the machine, a warning indicator for generating a signal when the locator enters any of the one or more safety zones, and a lamp associated with the person. The lamp may be a spot lamp for illuminating the area around the person, and it may also include one or more warning lamps associated with the warning indicator such that the one or more warning lamps are illuminated when the locator enters either of the safety zones.

Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.

Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.

Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.

Abstract: The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRH1 Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL1 Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain.

Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

Abstract: CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.

Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.

Abstract: A cargo body wall including one or more panels having interior and exterior sides. A plurality of primary logistics tracks are elongated in a first direction and have first and second portions spaced along the first direction with a hat-shaped profile in cross-section. The first and second portions include logistics fitting openings. The primary logistics tracks are secured to the one or more wall panels at the interior side such that the first and second portions project inward of an interior plane of the wall panel(s). A secondary logistics track is elongated in a second direction and has logistics fitting openings. The secondary logistics track is secured such that the first and second directions intersect and the secondary logistics track crosses each of the plurality of primary logistics tracks at a position between the first and second portions thereof.

Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1 : PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mA.b 5, PD-1 mA.b 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1 -binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1 -binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.

Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Abstract: A cargo body wall including an interior side defining an interior plane for facing a cargo receiving volume, and an exterior side. A primary logistics track is elongated in a first direction and situated in the cargo body wall, and a secondary logistics track is elongated in a second direction intersecting the first direction. The primary logistics track includes first and second inward expansions projecting inward of the interior plane, each of the first and second inward expansions having at least one opening therein providing access to a logistics fitting accommodation area within the cargo body wall. The secondary logistics track is arranged to cross the primary logistics track at a position between the first and second inward expansions.

Abstract: A system and method for providing secure access to an organization's internal directory service from external hosted services. The system includes a remote directory service configured to accept directory service queries from an application running on hosted services. The remote directory service passes the queries to a directory service proxy server inside a firewall of the organization via a secure connection service. The directory service proxy server passes the queries to the internal directory service inside said firewall. Request responses from the internal directory service pass through the directory service proxy server to the remote directory service through said firewall via the secure connection service. The remote directory service returns the response to the requesting application.